Биоаналоги: разработка и изучение с помощью современных биотехнологий

Биоаналоги — это биологические лекарственные препараты, имеющие сопоставимый с оригинальными биопрепаратами клинический профиль (профиль эффективности и безопасности), но разрабатываемые по сокращенной программе. Для разработки биоаналогов используется специальный подход на основе обратной инженерии, предполагающий глубокий анализ оригинального биопрепарата и последующее создание его версии, максимально близкой к нему по структурным и функциональным свойствам. Такой подход включает оценку и сравнение биоаналога и оригинального биопрепарата с точки зрения структуры молекулы и профиля примесей и их биологической активности в условиях in vitro, а также фармакокинетических, фармакодинамических и иммунологических свойств на людях. При необходимости могут быть проведены исследования на животных и клинические исследования III фазы, если остается неопределенность с точки зрения биоаналогичности, которую не удалось устранить с помощью предыдущих исследований и испытаний. Любые потенциально неизбежные остающиеся различия должны быть незначимы для профиля безопасности и эффективности. Современные методы биотехнологии и аналитики при соблюдении соответствующих научно-регуляторных требований позволяют создавать биоаналоги, клинический профиль которых сопоставим с таковым оригинального биопрепарата. Накопленный международный опыт свидетельствует о том, что не должно возникать явных проблем, обусловленных несопоставимостью между биоаналогом и оригинальным биопрепаратом, если выполнены применимые научные стандарты и регуляторные предписания.

1. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs — Humulin R. Official website of the U.S. Food and Drug Administration. [Internet]. 1982 October 28. [cited: 2020 May 3]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018780

2. Beals JM, et al. Insulin. D.J.A. In: Crommelin, et al. Pharmaceutical Biotechnology: Fundamentals and Applications. New York, USA: Springer Science+Business Media; 2013.

3. Co-ordination Group for Mutual Recognition and Decentralised procedures — Human (CMDh). CMDh Questions & Answers on Biologicals, CMDh/269/2012, Rev. 2. Heads of Medicines Agencies (HMA). [Internet]. 2020 February. [cited: 2020 June 6]. Available from: https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_269_2012_Rev._2_2020_02_clean_Q_A_on_biologicals.pdf

4. Dübel S. Handbook of Therapeutic Antibodies: Technologies, Emerging Developments and Approved Therapeutics. Weinheim, Germany: Wiley-VCH Verlag; 2010.

5. Geigert J. Biopharmaceuticals Are Not Chemical Drugs. In: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals, 2nd ediditon. Carlsbad, CA: Springer International Publishing; 2013.

6. Geigert J. Demonstrating Product Comparability After Process Changes. In: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals, 3rd ed. Cham, Switzerland: Springer Nature Switzerland AG; 2019.

7. U.S. Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Internet]. 2015 April 28. [cited: 2020 May 29]. Available from: https://www.fda.gov/media/82647/download.

8. Considerations in Demonstrating Interchangeability With a Reference Product, Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Internet]. 2019 May 10. [cited: 2020 June 5]. Available from: https://www.fda.gov/media/124907/download

9. Evans DB, Hsu J, Boerma T. Universal health coverage and universal access. Bull World Health Organ. 2013;91(8):546-546A. https://doi.org/10.2471/BLT.13.125450

10. Health Canada. Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. Official website of the Government of Canada. [Internet]. 2016 November 14. [cited: 2020 June 6]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs-1.html

11. European Medicenes Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/ BMWP/42832/2005). Official Website of European Medicenes Agency. [Internet]. 2006 February 22. [cited: 2020 May 29.]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-1.pdf

12. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977, 2009. Official website of the World Health Organisation. [Internet]. 2013. [cited: 2020 May 31]. Available from: https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1

13. European Medicenes Agency. Guideline on similar biological medicinal products (Rev.1). Official Website of European Medicenes Agency. [Internet]. 2014 October 23. [cited: 2020 May 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf

14. U.S. Congress. U.S. Code, Title 42, Section 262. Regulation of biological products. Legal Information Institute, Cornell Law School. [Internet]. 2010 March 23. [cited: 2020 June 6]. Available from: https://www.law.cornell.edu/uscode/text/42/262

15. Frazier KC. Affording Medicines for Today’s Patients and Sustaining Innovation for Tomorrow. JAMA. 2020;323(9):831. https://doi.org/10.1001/jama.2020.0167

16. Association for Accessible Medicines. 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report: The Case for Competition. Official website of the Association for Accessible Medicines. [Internet]. 2019. [cited: 2020 May 10]. Available from: https://accessiblemeds.org/sites/default/files/2019-09/AAM-2019-Generic-Biosimilars-Access-and-Savings-US-Report-WEB.pdf

17. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs --Summary review for Zarxio, BLA 125553. Official website of the U.S. Food and Drug Administration. [Internet]. U.S. Food and Drug Administration, 2015 March 6. [cited: 2020 May 10]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125553

18. Medicines for Europe. Infographic: Key Figures on Generic Medicines. Official website of the Medicines for Europe. [Internet]. Medicines for Europe, 2006 February 22. [cited: 2020 May 10]. Available from: https://www.medicinesforeurope.com/generic-medicines/whats-new/?t=infographics

19. European Medicenes Agency. Guideline on the investigation of bioequivalence (Rev.1). Official Website of European Medicenes Agency. [Internet]. 2010 January 20. [cited: 2020 June 5]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf

20. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability; WHO Technical Report Series. Official website of the World Health Organisation. [Internet]. 2017 June. [cited: 2020 June 5]. Available from: http://academy.gmp-compliance.org/guidemgr/files/who_trs1003_annex6.pdf

21. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Choice of Control Group and Related Issues in Clinical Trials (E10). Official Website of the ICH. [Internet]. 2000 July 20. [cited: 2020 May 27]. Available from: https://database.ich.org/sites/default/files/E10_Guideline.pdf

22. European Parliament, Council. Recital 6 of Directive 2001/20/ EC of the European Parliament and of the Council of 4 April 2001. EUR-Lex. [Internet]. 2009 August 7. [cited: 2020 June 6]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1591199062581&uri=CELEX:32001L0020

23. Aranha H. Disposable systems, one more manufacturing option. BioPocess Int. 2004;10:6-16.

24. European Medicines Agency. EMA Regulatory Science to 2025: Strategic reflection (draft). Official website of European Medicines Agency. [Internet]. 2019. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf

25. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431. https://doi.org/10.1038/nrd4309

26. Morgan P, Brown DG, Lennard S, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17(3):167-181. https://doi.org/10.1038/nrd.2017.244

27. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). General Considerations for Clinical Trials, E8. Official Website of the ICH. [Internet]. 1997 July 17. [cited: 2020 June 8]. Available from: https://database.ich.org/sites/default/files/E8_Guideline.pdf

28. European Parliament, Council. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. EUR-Lex. [Internet]. 2019 July 26. [cited: 2020 June 6]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1591447794819&uri=CELEX:02001L0083-20190726

29. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239-1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x

30. European Medicenes Agency. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, Revision 1. Official Website of European Medicenes Agency. [Internet]. 2014 December 18. [cited: 2020 June 8]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf

31. Visser J, Feuerstein I, Stangler T, et al. Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab. BioDrugs. 2013;27(5):495-507. https://doi.org/10.1007/s40259-013-0036-3

32. Dougherty MK, Zineh I, Christl L. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States. Clin Pharmacol Ther. 2018;103(1):36-38. https://doi.org/10.1002/cpt.909

33. U.S. Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product: Guidance Document. Official Website of the U.S. Food and Drug Administration. [Internet]. 2016 December 29. [cited: 2020 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product

34. Ghezlou M, Mokhtari F, Kalbasi A, et al. Aggregate Forms of Recombinant Human Erythropoietin With Different Charge Profile Substantially Impact Biological Activities. J Pharm Sci. 2020;109(1):277-283. https://doi.org/10.1016/j.xphs.2019.05.036

35. European Medicenes Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Official Website of European Medicenes Agency. [Internet]. 2014 May 22. [cited: 2020 May 29]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf

36. U.S. Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product, Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Internet]. 2015 April 30. [cited: 2020 June 5]. Available from: https://www.fda.gov/media/135612/download

37. European Parliament, Council. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex. [Internet]. 2004 March 31. [cited: 2020 June 9]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32004L0027

38. European Medicenes Agency. Guideline on similar biological medicinal products — First version. Official Website of European Medicenes Agency. [Internet]. 2005 October 30. [cited: 2020 June 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-first-version_en.pdf

39. Omnitrope: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2006 April 25. [cited: 2020 May 18]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/omnitrope-epar-scientific-discussion_en.pdf

40. Zarsio: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2009 February 16. [cited: 2020 May 18]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zarzio-epar-public-assessment-report_en.pdf

41. U.S. Food and Drug Administration. Drugs@FDA: Approval Package for Zarxio (filgrastim-sndz) — Chemistry Review(s). Official Website of the U.S. Food and Drug Administration. [Internet]. 2015 March 6. [cited: 2020 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000ChemR.pdf

42. Drugs@FDA: Approval Package for Zarxio (filgrastim-sndz) — Pharmacology Review(s). Official Website of the U.S. Food and Drug Administration. [Internet]. 2015 March 6. [cited: 2020 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000PharmR.pdf

43. Drugs@FDA: Approval Package for Zarxio (filgrastim-sndz) — Clinical Pharmacology and Biopharmaceutics Review(s). Official Website of the U.S. Food and Drug Administration. [Internet]. 2015 March 6. [cited: 2020 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000ClinPharmR.pdf

44. European Medicenes Agency. Inflectra : European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2013 October 4. [cited: 2020 May 18]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/inflectra-epar-public-assessment-report_en.pdf

45. U.S. Food and Drug Administration. Drugs@FDA: Approval Package for Inflectra (infliximab-dyyb) — Chemistry Review(s). Official Website of the U.S. Food and Drug Administration. [Internet]. 2016 April 5. [cited: 2020 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000ChemR.pdf

46. Cilia M, Ruiz S, Richardson P, et al. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency’s Committee for Medicinal Products for Human Use. AAPS PharmSciTech. 2018;19(2):489-511. https://doi.org/10.1208/s12249-017-0892-0

47. Mielke J, Innerbichler F, Schiestl M, et al. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal. AAPS J. 2019;21(1):7. https://doi.org/10.1208/s12248-018-0275-9

48. European Medicenes Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues — Revision 1. Official Website of European Medicenes Agency. [Internet]. 2015 February 26. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-0.pdf

49. Li J, Florian J, Campbell E, et al. Advancing Biosimilar Development Using Pharmacodynamic Biomarkers in Clinical Pharmacology Studies. Clin Pharmacol Ther. 2020;107(1):40-42. https://doi.org/10.1002/cpt.1653

50. European Medicines Agency. Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) — Revision 1. Official website of European Medicines Agency. [Internet]. 2018 August 15. [cited: 2020 July 19]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-recombinant-granulocyte-colony_en.pdf

51. Barbier L, Ebbers HC, Declerck P, et al. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther. 2020;108(4):734-755. https://doi.org/10.1002/cpt.1836

52. U.S. Food and Drug Administration. Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Internet]. 2019 November 25. [cited: 2020 June 9]. Available from: https://www.fda.gov/media/133014/download

53. European Medicenes Agency. Semglee: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2018 June 4. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/semglee-epar-public-assessment-report_en.pdf

54. Insulin lispro Sanofi: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2017 May 18. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/insulin-lispro-sanofi-epar-public-assessment-report_en.pdf

55. Майоров А.Ю., Федотов И.А., Драй Р.В., и др. Результаты оценки биоподобия препаратов РинЛиз® (ООО «ГЕРОФАРМ», Россия) и Хумалог® («Лилли Франс», Франция) с использованием метода гиперинсулинемического эугликемического клэмпа на здоровых добровольцах // Разработка и регистрация лекарственных средств. — 2020. — Т. 9. — No2. — С. 124-131. https://doi.org/10.33380/2305-2066-2020-9-2-124-131

56. European Medicenes Agency. Idacio : European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2019 April 17. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf

57. Cegfila (previously Pegfilgrastim Mundipharma) : European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2020 Februay 12. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/ documents/assessment-report/pegfilgrastim-mundipharma-epar-public-assessment-report_en.pdf

58. Udenyc: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2018 October 23. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/udenyca-epar-public-assessment-report_.pdf

59. Ritemvia: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2017 August 15. [cited: 2020 May 21]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ritemvia-epar-public-assessment-report_en.pdf

60. Kanjinti: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2018 May 30. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/kanjinti-epar-public-assessment-report_en.pdf

61. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191-3196. https://doi.org/10.1182/blood-2014-06-583617

62. Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21-50. https://doi.org/10.1146/annurev.immunol.25.022106.141702

63. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-665. https://doi.org/10.1182/blood-2011-04-325225

64. European Medicenes Agency. Ruxience: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2020 April 7. [cited: 2020 May 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ruxience-epar-public-assessment-report_en.pdf.

65. U.S. Food and Drug Administration. Drugs@FDA: Approval Package for TRUXIMA (rituximab-abbs). Official Website of the U.S. Food and Drug Administration. [Internet]. 2018 November 28. [cited: 2020 May 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761088Orig1s000TOC.cfm

66. European Medicenes Agency. Riximyo: European Public Assessment Report — Scientific Discussion. Official Website of European Medicenes Agency. [Internet]. 2017 April 21. [cited: 2020 May 23]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/riximyo-epar-public-assessment-report_en.pdf

67. Миронов А.Н., Васильев А.Н. Гавришина Е.В., Ниязов Р.Р. Взаимозаменяемость лекарственных препаратов: зарубежный опыт, препятствия и условия становления концепции в России, роль научной экспертизы // Ремедиум. — 2013. — No10. — С. 8-19.